Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: A controlled, open 24-month study of 246 patients
| Autor: | Rodolfo M. Antonello, Giuseppe Cazzato, Tatiana Cattaruzza, Paola Torre, Rita Moretti |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Phenylcarbamates Rivastigmine Brain damage Neuropsychological Tests behavioral disciplines and activities 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine mental disorders Humans Medicine Dementia Vascular dementia Antihypertensive Agents Aged Cholinesterase Aged 80 and over biology Lewy body business.industry Dementia Vascular General Neuroscience Delirium medicine.disease Acetylcholinesterase nervous system diseases 030227 psychiatry Psychiatry and Mental health Clinical Psychology chemistry Anesthesia Hypertension biology.protein Female Cholinesterase Inhibitors Geriatrics and Gerontology medicine.symptom business 030217 neurology & neurosurgery Follow-Up Studies medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1938-2731 1533-3175 |
| DOI: | 10.1177/153331750401900607 |
| Popis: | The goal of this study was to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effect on delirium in vascular dementia (VaD). The results from this follow-up study suggest that although delirium is frequent in elderly, cognitively impaired patients, it might not be a simple consequence of acute disease and hospitalization. Rather, delirium can be secondary to brain damage and to metabolic disturbances. According to the Lewy body dementia model, delirium could be induced by a lack of acetylcholine in the brain. Rivastigmine may help reduce the frequency of delirium episodes and help shorten their duration. Additional studies are required to better define the causes of delirium, which currently has no definitive treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|